---
title: "De novo design and AlphaFold3 evaluation of site-specific protein binders targeting MAP4K4"
id: "biorxiv-10-de-novo-design-and-alphafold3-evaluation-of-protein-binders-targeting-specific"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-10-de-novo-design-and-alphafold3-evaluation-of-protein-binders-targeting-specific"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.04.749196v1?rss=1"
published_at: "2026-09-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# De novo design and AlphaFold3 evaluation of site-specific protein binders targeting MAP4K4
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-10-de-novo-design-and-alphafold3-evaluation-of-protein-binders-targeting-specific
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.04.749196v1?rss=1)
- **Published At:** 2026-09-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study reports a computational pipeline for **de novo design** of small protein binders (≈50–130 residues) that target defined surface hotspots on the serine/threonine kinase **MAP4K4**. - Authors combined generative and sequence-design tools (RFdiffusion, ProteinMPNN) plus AlphaFold-based evaluation; they also tested an integrated one-shot tool, **BindCraft**. - An automated hotspot-detection algorithm was developed that weights geometry, chemistry, structural rigidity, and AlphaFold pLDDT to select target surface sites. - From thousands of computational candidates, 20 promising designs were evaluated using **AlphaFold3 (AF3)** for complex prediction; predicted interface-template modeling (**ipTM**) scores ranged from 0.16 to 0.90. - Nine designs had ipTM ≥ 0.80 and five scored ≥ 0.87, indicating high AF3 confidence for several binders. - Two high-confidence binders target non-overlapping hotspots on opposite faces of MAP4K4, suggesting suitability as a sandwich-pair for assay applications. - BLASTp searches showed only low-significance matches for about half of the designed sequences, indicating novelty and exploration of new sequence space rather than recovery of known motifs. - Five complexes representing the AF3 confidence spectrum underwent 100-ns explicit-solvent molecular dynamics; interchain contacts were retained in all, but stability varied between systems. - Specificity assessment used AF3 to compare binder interactions with MAP4K4 versus CDK2 (negative-control kinase); ipTM values dropped significantly against CDK2 (p = 0.0039), supporting predicted specificity. - In silico safety screens (ToxinPred2, AlgPred 2.0) flagged one candidate as a potential allergen and two as potential toxins. - The authors conclude that publicly available computational tools and modest resources can produce site-specific protein probes for an under-served target, supporting broader participation in protein engineering by public and amateur scientists.
## Clinical Analysis & Structured Key Points
De Novo Design and AlphaFold3 Evaluation of Protein Binders Targeting Specific Sites of MAP4K4 | bioRxiv Skip to main content New Results De Novo Design and AlphaFold3 Evaluation of Protein Binders Targeting Specific Sites of MAP4K4 Aarnav Jain , View ORCID Profile Alexander V Tobias doi: https://doi.org/10.64898/2026.09.04.749196 Aarnav Jain 1 Illinois Mathematics and Science Academy; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: ajain{at}imsa.edu Alexander V Tobias 2 Throop Research Academy Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Alexander V Tobias Abstract Info/History Metrics Supplementary material Preview PDF Abstract MAP4K4 is a serine/threonine kinase member of the mitogen activated protein kinase family. It acts through the JNK, p38 MAPK, and ERK1/2 pathways and is implicated in cancer proliferation and invasion, TNF-α-driven insulin resistance, macrophage-mediated inflammation, and cardiomyocyte apoptosis in heart failure. No selective small-molecule inhibitor of MAP4K4 has reached clinical use, and knowledge of the specific epitopes on MAP4K4 is lacking for some existing antibodies, leaving a role for small protein binders directed at specific surface sites. We used a computational pipeline that combines RFdiffusion, ProteinMPNN, and AlphaFold2, as well as BindCraft, an integrated "one-shot" tool, for de novo design of small protein binders (~50–130 residues) to specific MAP4K4 surface hotspots. We also created an automated hotspot determination algorithm that weighs geometry, chemistry, rigidity, and AlphaFold pLDDT. From thousands of candidate sequences, we evaluated 20 of the most promising binders with AlphaFold3 (AF3). The interface predicted template modeling (ipTM) scores ranged from 0.16 to 0.90, with nine candidates having ipTM ≥ 0.80, and five scoring ≥ 0.87. Two binders engage non-overlapping hotspots on opposite faces of MAP4K4, making them a candidate pair for a sandwich assay. BLASTp searches of all designed protein sequences returned only low-significance matches to half of them, indicating that they represent truly novel binding solutions and previously unexplored regions of protein sequence space rather than rediscovered natural motifs. We subjected five complexes spanning the observed AF3 confidence range to 100-ns explicit-solvent molecular dynamics simulation. Interchain contacts were retained throughout, with stability varying substantially between systems. Confidence in the binding specificity of the nine highest-confidence candidates was bolstered by juxtaposition with AF3 evaluations of their interaction with CDK2, a negative-control kinase. This comparison yielded a significant, consistent reduction in ipTM (p = 0.0039) for the control binding partner. ToxinPred2 and AlgPred 2.0 screening suggested that one candidate was a potential allergen and two were potential toxins. These results support that de novo design of small, site-specific protein probes for an underserved disease target is achievable using free, publicly available computational tools and minimal resources, pointing to a greater role for the public and amateur scientists to contribute to biotechnological advancement. Competing Interest Statement The authors have declared no competing interest. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 07, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following De Novo Design and AlphaFold3 Evaluation of Protein Binders Targeting Specific Sites of MAP4K4 Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share De Novo Design and AlphaFold3 Evaluation of Protein Binders Targeting Specific Sites of MAP4K4 Aarnav Jain , Alexander V Tobias bioRxiv 2026.09.04.749196; doi: https://doi.org/10.64898/2026.09.04.749196 Share This Article: Copy Citation Tools De Novo Design and AlphaFold3 Evaluation of Protein Binders Targeting Specific Sites of MAP4K4 Aarnav Jain , Alexander V Tobias bioRxiv 2026.09.04.749196; doi: https://doi.org/10.64898/2026.09.04.749196 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (7969) Biochemistry (18623) Bioengineering (14765) Bioinformatics (44155) Biophysics (22458) Cancer Biology (19585) Cell Biology (26737) Clinical Trials (138) Developmental Biology (13900) Ecology (20880) Epidemiology (2067) Evolutionary Biology (25315) Genetics (16100) Genomics (23400) Immunology (18608) Microbiology (42209) Molecular Biology (17939) Neuroscience (92895) Paleontology (693) Pathology (2969) Pharmacology and Toxicology (5063) Physiology (8064) Plant Biology (15901) Scientific Communication and Education (2091) Synthetic Biology (4538) Systems Biology (10184) Zoology (2376)
## Related Clinical Research

- [Ulcerative Bullosis Diabeticorum Linked to Uncontrolled Type 2 Diabetes and Social Barriers](https://medichelpline.com/clinical-feed/pubmed-42768731.md) (DOI: 10.12659/AJCR.953149)
- [Predicting Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Risk Factors and Nomogram Model](https://medichelpline.com/clinical-feed/pubmed-42763210.md) (DOI: 10.3760/cma.j.cn112137-20260410-00979)
- [Trump administration announces nine additional drug pricing deals with manufacturers](https://medichelpline.com/clinical-feed/stat-news-1-trump-strikes-nine-more-deals-with-drugmakers-to-lower-prices.md)
- [Link Between Metabolic Score, Insulin Resistance, Uric Acid, and Thyroid Nodules](https://medichelpline.com/clinical-feed/plos-one-6-associations-of-the-metabolic-score-for-insulin-resistance-and-uric-acid-with.md)
- [Diagnostic accuracy of GH stimulation tests after hypothalamic–pituitary radiotherapy: systematic](https://medichelpline.com/clinical-feed/bmj-open-9-diagnostic-accuracy-of-growth-hormone-stimulation-tests-for-growth-hormone.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.